Table 2. List of significant gastric cancer genes evaluated in independent studies between 2012 and 2015.
| Symbol | Affy ID | Gene name | Ref. | First progression HR (95% CI), p | Overall survival HR (95% CI), p |
|---|---|---|---|---|---|
| BECN1 | 208946_s_at | Beclin-1 | [44] | HR = 0.68 (0.55–0.84)p = 0.00042 | HR = 0.68 (0.57–0.81) p= 1.5e-05 |
| BIRC5 | 202094_at | Survivin | [25] | HR = 1.52 (1.22–1.89)p = 0.00016 | HR = 1.45 (1.2–1.75) p= 1e-04 |
| CASP3 | 202763_at | Caspase-3 | [21] | HR = 0.52 (0.42–0.64)p = 3e-10 | HR = 0.5 (0.42–0.6) p = 6e-14 |
| CNTN1 | 211203_s_at | Contactin-1 | [19] | HR = 1.41 (1.15–1.73)p = 0.0011 | HR = 1.44 (1.21–1.7) p = 3.5e-05 |
| COX2 | 204748_at | Cyclooxygenase-2 | [16] | HR = 0.73 (0.59–0.91)p = 0.0056 | HR = 0.72 (0.59–0.88) p= 0.0013 |
| CTGF | 209101_at | Connective tissue growth factor | [22] | HR = 0.71 (0.58–0.89p = 0.0022 | HR = 0.72 (0.59–0.87) p= 0.00051 |
| CTNNB1 | 201533_at | Beta-catenin | [18] | HR = 0.52 (0.42–0.64)p = 3.2e-10 | HR = 0.47 (0.38–0.57) p= 4.3e-15 |
| EGFR | 201983_s_at | Epidermal growth factor receptor | [12] | HR = 1.85 (1.49–2.29)p = 1.6e-08 | HR = 1.86 (1.54–2.25) p= 8.5e-11 |
| ERCC1 | 203720_s_at | Excision repair complementation group 1 | [45] | HR = 1.38 (1.12–1.69) p = 0.002 | HR = 1.36 (1.13–1.63) p= 0.0012 |
| HER2 | 216836_s_at | Human epidermal growth factor receptor 2 | [46] | HR = 1.38 (1.12–1.69)p = 0.0021 | HR = 1.41 (1.18–1.68) p= 0.00011 |
| HIF1a | 200989_at | Hypoxia-inducible factors-1 alpha | [14] | n.s. | HR = 0.73 (0.62–0.87) p= 0.00036 |
| MET (HGFR) | 203510_at | Hepatocyte growth factor receptor | [47] | HR = 0.69 (0.55–0.87)p = 0.0018 | HR = 0.63 (0.51–0.77) p= 1.3e-05 |
| MMP-2 | 201069_at | Matrix metalloproteinase 2 | [24] | HR = 1.64 (1.33–2.02)p = 2.8e-06 | HR = 1.78 (1.47–2.16) p= 2.6e-09 |
| NOV | 200724_at | Nephroblastoma Overexpressed | [22] | n.s. | HR = 1.45 (1.22–1.72) p = 1.7e-05 |
| PFKB4 | 206246_at | 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4 | [48] | HR = 1.7 (1.33–2.19) p = 2.5e-05 | HR = 1.56 (1.32–1.86) p= 3.2e-07 |
| SIRT1 | 218878_s_at | Silent mating type information regulation 1 | [49] | HR = 0.56 (0.45–0.7) p = 1.1e-07 | HR = 0.64 (0.54–0.76) p= 2.2e-07 |
| SPHK1 | 219257_s_at | Sphingosine kinase 1 | [50] | HR = 1.62 (1.31–1.99)p = 5.6e-06 | HR = 1.61 (1.31–1.96) p= 3.1e-06 |
| SP1 | 214732_at | Specificity protein 1 | [20] | HR = 1.47 (1.19–1.82)p = 4e-04 | HR = 1.45 (1.23–1.72) p= 1.6e-05 |
| SPARC | 212667_at | Secreted protein acidic and rich in cysteine | [51] | HR = 1.34 (1.08–1.66)p = 0.007 | n.s. |
| TIMP-1 | 201666_at | Tissue inhibitor of metalloproteinase-1 | [23] | HR = 1.77 (1.42–2.22)p = 3.9e-07 | HR = 1.92 (1.57–2.36) p= 2.2e-10 |
| VEGF | 210512_s_at | Vascular endothelial growth factor | [15] | HR = 1.75 (1.41–2.17)p = 2.9e-07 | HR = 1.53 (1.27–1.85) p= 5.7e-06 |
Statistical test: Cox univariate regression analysis, HR: hazard rate, CI: confidence interval, n.s.: p value over the 5% FDR cutoff. Bold: see survival plots in Figure 2.